Sydney Jennings

New 4-year data from the ADlong trial show lebrikizumab achieved EASI-75 in 94% of atopic dermatitis patients on once-monthly maintenance dosing.

Episode highlights include a new AD blood test for PCPs, sleep effects of elinzanetant among postmenopausal women, lung cancer screening gains, and more.

Your daily dose of the clinical news you may have missed.

COVID-19 infection increased risks of AKI, CKD, and ESRD vs influenza in a 3 million–patient US study, highlighting need for kidney monitoring.

New data to be presented at ACC 2026 shows 6 hours of daily screen time may lead to higher BP, LDL-C, BMI, and nicotine use, independent of exercise.

Your daily dose of the clinical news you may have missed.

Replacing 30 minutes of sedentary time with sleep or exercise was linked to lower insulin resistance in teens in preliminary AHA EPI 2026 data.

Test your knowledge of added sugar limits, processed food reduction, and label interpretation in the 2025–2030 Dietary Guidelines.

New FDA-approved semaglutide 7.2 mg shows ~21% weight loss, offering primary care clinicians a higher-efficacy obesity treatment option.

FDA clears MiniMed Flex insulin pump with smartphone control and adaptive algorithm for type 1 and insulin-requiring type 2 diabetes.

Test your knowledge of saturated fat thresholds, sodium limits, and alcohol recommendations in the 2025–2030 Dietary Guidelines.

ATTD 2026: Registry data from US primary care practices showed Dexcom G7 use lowered HbA1c by 0.7% over 1 year in adults with noninsulin-treated type 2 diabetes.

A COSMOS trial analysis found daily multivitamin use modestly slowed epigenetic markers of biological aging in older adults over 2 years.

A new study shows virtual physician apps replace about half of clinic visits for young adults, while the rest adds new, low-risk demand.

Assess your knowledge of fiber targets, fruit and vegetable serving goals, and microbiome guidance in the 2025–2030 Dietary Guidelines.

Deucravacitinib (Sotyktu) is the first TYK2 inhibitor approved for the treatment of PsA.

Five trials presented at AAAAI 2026 highlight new therapies and prevention strategies for hereditary angioedema, atopic dermatitis, asthma, and chronic urticaria.

Large study links DASH and other healthy diets

New FDA approvals span swallowable obesity balloon, dupilumab for fungal sinusitis, oral desmopressin, updated menopause labels, and sildenafil film.

New data highlight digital dementia risk scores, plasma p-tau217 prediction, and patient-centered endpoints in Alzheimer disease research.

The FDA issued 30 warning letters to telehealth firms for false or misleading claims about compounded GLP-1 products, citing illegal marketing practices.

ACP updates RSV vaccine guidance: adults 75+ get a one-time protein subunit shot; higher-risk ages 60–74 may consider it to prevent hospitalization.

Review key updates to the Dietary Guidelines for Americans to support patient counseling, nutritional assessments, and evidence-based interventions.

AAAAI 2026: In LIBERTY-CSU CUPID, dupilumab reduced ISS7 and UAS7 at 24 weeks across BMI, angioedema, and gender subgroups in CSU.

FDA approves DESMODA, a ready-to-use desmopressin acetate oral solution, enabling precise titration for central diabetes insipidus with key hyponatremia warnings.

FDA approves dupilumab for allergic fungal rhinosinusitis ages 6+, cutting sinus blockage, polyps and smell loss while sharply reducing repeat surgery and steroid use.

In a phase 2 trial in China, UBT251 led to up to 19.7% mean weight loss at 24 weeks vs 2.0% with placebo in adults with overweight or obesity.

In the REDEFINE 4 trial, CagriSema led to 23% weight loss at 84 weeks but did not demonstrate noninferiority to tirzepatide 15 mg in adults with obesity.

In 142 000 adults, adding Galleri to standard screening reduced stage IV diagnoses over time in a prespecified group of 12 cancers, according to new data.

SMART trial finds clesrovimab protects high-risk children in a second RSV season, with consistent safety and fewer RSV-related hospitalizations.